Although Eli Lilly And Co (NYSE:LLY) reported its fourth-quarter revenues and earnings ahead of consensus estimates, backed by higher sales of Zepbound and Mounjaro, according to Scotiabank.
The Eli Lilly Analyst: Analyst Louise Chen maintained a Sector Outperform rating, while raising the price target from $1,165 to $1,300.
The Eli Lilly Thesis: The company reported sales and earnings of $19,292 million and $7.54 per share, topping consensus estimates of $17,944 million and $6.91 per share, respectively, Chen said in the note.
Check out other analyst stock ratings.
Zepbound sales came in at $4,261 million, higher than …